Objective: In this study, we examined the effect of iridoid (I) derived from lyophilized aqueous extract of Ajuga iva on serum HDL2 and HDL3 compositions and lecithin:cholesterol acyltransferase (LCAT) activity, enzyme responsible for reverse cholesterol transport.
Introduction
Coronary heart disease (CHD) is the most common cardiovascular disease and atherosclerosis is considered as the most frequent cause of CHD [1] varying with time and population but more prominently with increased prosperity and longevity [2] . Lipoproteins are closely related to the risk of cardiovascular diseases, as follows: lowdensity lipoproteins (LDL) indicate an increased risk, and high-density lipoproteins (HDL) are considered a protective factor [3] , because of its central role in reverse cholesterol transport [4] . Reverse cholesterol transport (RCT) is a complex process ensuring the efflux of cholesterol from peripheral cells and its transport back in the liver for its metabolism and biliary excretion [5] . The plasma enzyme lecithin:cholesterol acyltransferase (LCAT, EC 2.3.1.43) is of central importance to the lipoproteins metabolism. It is a key enzyme involved in the maturation of lipoproteins [6] and in the generation of cholesteryl esters in HDL, and is fundamental to the processes of reverse cholesterol transport [7] , a mechanism generally held to be atheroprotective [8] .
Plants have the potential to reduce lipid and cholesterol in body and encourage safety profile [9] . The presence of bioactive compounds in some plants involved reduction in lipids and cholesterol [10] . Ajuga iva (L.) Schreber (Labiatae) is used as an antihelmintic, against intestinal disorders [11] , and as a diuretic agent [12] . According to ethnobotanical data collected in oriental Morocco by Ziyyat et al [13] , Ajuga iva, locally known as 'Chendgoura', is also alleged to possess hypoglycemic activity and it is believed by many
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Moroccan diabetics that the decoction of this plant consumed over a long time removes the cause of diabetes. Iridoids are found in many medicinal plants and may be responsible for some of their pharmaceutical activities. Isolated and purified, iridoids exhibit a wide range of bioactivities including cardiovascular [14] and hypolipidemic activities [15] .
We hypothesized that consuming iridoid from Ajuga iva may involve changes in serum LCAT activity. First we tested the effect on serum lipids. Second we determined the effect on serum HDL 2 and HDL 3 amounts and composition. Third we evaluated if iridoid had an effect on LCAT activity in hypercholesterolemic rats.
Materials and methods

Preparation of the aqueous extract of Ajuga iva
Mature whole Ajuga iva (L) Schreber (Lamiaceae) (No. 2345) plants were collected in November 2004 from Bechar, southwest of Algeria, and stored at room temperature in a dry place before use. The arial parts of Ajuga iva plant were dried at ambient temperature. Afterward, 500 mL of distilled water was added to 50 g of arial plant finely powered, the mixture was heated under reflux for 60 min, and then the decoction was filtered. The filtrate was frozen at -20ºC and lyophilized. The crude yield of the lyophilized material was approximately 18% w/w; it was stored at ambient temperature until further use [16] .
Extraction and isolation of iridoid from Ajuga iva
Aqueous extract of Ajuga iva was added to H 2 Osaturated n-butanol. After mixing, the supernatant was recuperated and evaporated to dryness in vacuum. The extract was submitted to a vacuum liquid chromatography on RP-C18 silica gel to eliminate the free sugar. Samples were subjected to flash chromatography to give different fractions. After evaporation of the solvent in vacuum, the fractions were diluted with H 2 O; and the crude yield of the lyophilized material was approximately 2% w/w. The compound in the aqueous extract of Ajuga iva was identified as iridoid, and especially 8-O-acetylharpagide by comparison with literature data [17] .
Animals and diets Male Wistar rats (n=24) (Iffa Credo, l'Arbresle, Lyon, France) weighing 120±5 g were used in this study. Experimental hypercholesterolemia was induced by feeding normocholesterolemic rats (with total cholesterol value of 2.40±0.62 mmol/L) 1% cholesterol-enriched diet for 15 days (Table 1) . After this phase, serum total cholesterol (TC) concentration was measured and the value was 2.7-fold higher than that in the beginning of the study (6.5±0.6 mmol/L).
Hypercholesterolemic (HC) rats were divided into four groups fed for 15 days with the same diet; 3 groups were treated by different doses (5, 10 or 15 mg/kg b.w, intraperitoneally) of iridoid and one group was untreated. Diets and tap water were freely available. Animals were kept in wire bottom cages at temperature of 24ºC, relative humidity of 60% and light were automatically turned on from 07:00 h to 19:00 h. We followed the 'General Guidelines for the Use of Living Animals in Scientific Investigations' [18] and protocol and use of rats were approved by the institutional committee on animal care and use.
Blood samples At day 15, rats were food deprived for 12 hours, anaesthetized with sodium pentobarbital (60 mg/kg b.w) and euthanized with overdose. Blood was collected from abdominal aorta into dried tubes and centrifuged at 4ºC, 1000g for 15 min. Serum aliquots were preserved in tubes containing 0.1% Na 2 -EDTA and 0.02% sodium azide for different assays.
Isolation and characterisation of serum HDL 2 and HDL 3 Serum high density lipoproteins, i.e. HDL 2 and HDL 3 , were determined by differential dextran sulphate magnesium chloride precipitation according to Burstein et al [19] . To estimate the validity of this method, ultracentrifugation according to Havel et al [20] was performed to quantitate lipoproteins. Total protein content of each lipoprotein fraction was measured by the method of Lowry et al [21] using bovine serum albumin as standard. Total cholesterol and triacyglycerols (TG) concentrations were determined by enzymatic colorimetric methods (kits purchased from Human GmbH, Wiesbaden, Germany) and unesterified cholesterol (UC) was estimated by the enzymatic method (kit from Boehringer, Meylan, France). Esterified cholesterol (EC) was calculated from the difference between total and unesterified cholesterol. EC value was multiplied by 1.67 times to obtain cholesterol esters amount. Analysis of phospholipids (PL) was assessed by enzymatic determination (BioMerieux, Lyon, France).
Assay for LCAT activity LCAT activity was determined by the conversion of [22] as modified by Knipping [23] . Cholesterol and egg phosphatidylcholines (PC) used for preparation of liposomes were purchased from Merck (Darmstadt, Germany). Radiolabelled 7(n)-[ 3 H] cholesterol was obtained from Amersham (Les Ullis, France). Specifically, 2 mg cholesterol and 16 mg egg PC in chloroformmethanol (2/1, v/v) were evaporated to dryness under a nitrogen stream. After adding 1 mL of (10 mM Tris-HCl, 150 mM NaCl and 1 mM EDTA, pH 7.4), the solution was sonicated for 30 min at 100 W and 25ºC with a sonifier (Bioblock Scientific, Strasbourg, Illkirch, France). The mixture was used within two days. The final cholesterol and PC contents were estimated according to the method of Assous & Girard [24] and with the CHOP-PAP test (kit from Boehringer, Mannheim, Germany), respectively. The final PC to cholesterol molar ratio was 4/1.
LCAT activity was determined using liposomes prepared by the procedure described above. For each assay, 88 nM of liposomes-cholesterol, 200 nCi [ 3 H] cholesterol and 40 mg of fatty acidfree albumin (Merck, Darmstadt, Germany) were mixed. This mixture was preincubated for 1 h at 37ºC, then 100 mL serum (enzymatic source) were added, together with 10 mL of 1 mmol mercaptoethanol per L (Merck). The amount of apoA1 in 100 mL of serum/mL assay mixture was sufficient for maximal activity when compared with other investigation by Knipping [23] The reaction was stopped by adding 20 volumes of chloroformmethanol (2/1, v/v). After 2 h, the mixture was filtered and the precipitate extracted three times with chloroform-methanol (2/1, v/v). The combined filtrate was concentrated in a vacuum and the water-free residue was extracted three times with 3 mL absolute ethanol (Prolabo, Paris, France). The lipid phase was evaporated to dryness and redissolved into 200 mL CHCl 3 , and 50 mL was applied on Kiesselgel G 60 plates (Merck). Lipids were separated with petroleum ether-diethyl etheracetic acid (60/30/1, v/v/v) and located by exposure to iodine vapour. After evaporation of iodine, the areas containing UC and EC were scrapped into a liquid scintillant in counting vials (Ready Solv HP/b, Beckman) and counted in a Beckman 7500 LS scintillation counter (Palo Alto, CA, USA). The cholesterol esterifying activity was expressed as µmol/h/L of serum.
Statistical analysis
Results were expressed as means ± SEM for 6 rats per group. Statistical evaluation of the data was carried out by the parametric Student t test. The calculations were performed using STATISTICA 6.0 for Windows software (StatSoft Inc., Tulsa, OK, USA). The limit of statistical significance was set at p<0.05 between the different groups treated or not with iridoids from Ajuga iva aqueous extract.
Results
Serum TC, TG, C-HDL 2 and C-HDL 3 contents
At day 15, serum TC concentration was 1.4-and 1.2-fold lower in the I 5 -HC and I 10 -HC groups compared with the HC group, respectively.
Serum TG values were significantly lower, 3-fold in the I 5 -HC group, 3.4-fold in the I 10 -HC group and 3.5-fold in the I 15 -HC group than the untreated group.
C-HDL 2 and C-HDL 3 values were increased 3.2-and 4-fold in the I 5 -HC group; 2.2-and 4.2-fold in the I 10 -HC group and 3.2-and 8.7-fold in the I 15 -HC group than the HC group, respectively (Table 2) .
Serum LCAT activity
Compared to untreated HC rats, different doses of iridoids treatment for 15 days showed that LCAT activity was 1.5-and 1.6-fold higher in the I 5 -HC and I 10 -HC groups than the HC group, respectively (Table 2) .
Serum HDL 2 amounts and composition
Compared to HC group, the HDL 2 amount, which was the sum of apolipoproteins (apo), TG, cholesteryl esters (CE), UC and PL contents (expressed in g/ L) were 4-, 4-and 2.5-fold higher in the I 5 -HC, I 10 -HC and I 15 -HC groups, respectively. Apo-HDL 2 concentrations were similar in all groups. The TG-HDL 2 value was higher, 3.8-fold in the I 5 -HC group, 4.2-fold in the I 10 -HC group and 2.4-fold in the I 15 -HC group, respectively. The PL-HDL 2 concentrations were 1.5-, 2.2-and 2-fold increased in the I 5 -HC, I 10 -HC and I 15 -HC groups. UC-HDL 2 contents were similar in all groups. CE-HDL 2 contents were increased, 4.3-fold in the I 5 -HC group, 3.8-fold in the I 10 -HC group and 2-fold in the I 15 -HC group (Table 3) .
Serum HDL 3 amounts and composition
The HDL 3 amount was 1.2-fold higher in the I 5 -HC group than the HC group. Apo contents were similar in all the groups. TG-HDL 3 values were 2.3-fold higher in the I 5 -HC group compared to the untreated HC group. PL contents were unchanged between groups. UC-HDL 3 values were higher, 3.3-fold in the I 5 -HC group, 2.8-fold in the I 10 -HC group and 3-fold in the I 15 -HC group than the HC group. CE-HDL 3 contents were 3.5-fold increased in the I 10 -HC group compared to the HC group (Table 4) .
Discussion
In the present study, we have demonstrated that iridoids from the lyophilized aqueous extract of Ajuga iva reduces cholesterolemia and triglyceridemia, affects serum HDL 2 and HDL 3 amounts and composition and increases LCAT activity in rat fed cholesterol-enriched diet. Our previous study has shown that Ajuga iva had no effect on TC in HC rats. This result has been explained, in part, by the similar values of lipid digestibility and fecal cholesterol excretion. In addition, Ajuga iva treated group ate more cholesterol (20 mg/d) compared to untreated group, which could be explained by enhanced C-HDL or/and in cholesterol used [25] . However, in the present study, the iridoids treatment at doses 5 or 10 mg/kg b.w decreased significantly TC, but there was no soustained hypocholesterolemia in rat receiving 15 mg/kg b.w dose. The possible underlying mechanism by which iridoids could exert its cholesterol lowering activities was not elucidated. At this stage of the study, several fundamental mechanisms can be proposed to explain our results. Iridoids may act by decreasing the cholesterol biosynthesis especially by decreasing the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase activity and/or by reducing the NADPH required for fatty acids and cholesterol synthesis. On the other hand, it can be suggested that iridoids led to a decrease in cholesterol absorption from the intestine and may have the ability to inhibit the intestinal absorption of bile acids and neutral steroids and to enhance hepatic cholesterol 7α-hydroxylase activity. Treatment with this iridoids could have a beneficial effect on dyslipidemia, particularly with the doses 5 and 10 mg/kg b.w. The TGs are carried in plasma lipoprotein to provide energy for peripheral tissues and are independently related to coronary heart disease [26] . In this study, the decrease of serum TG level in the iridoids treated rats compared to the untreated rats was an important finding. Indeed, in the HC rats treated with Ajuga iva aqueous extract, a decrease in serum TG was observed compared to the untreated rats [16] . A reasonable explanation was the assumption that elevated post-heparin lipolytic activity, observed in Ajuga iva treated group (data not published) was sufficient to abolish the hypertriglyceridemia anticipated with cholesterol feeding.
Dyslipidemia is a primary risk factor for cardiovascular disease, peripheral vascular disease, and stroke. Current guidelines recommend diet as first-line therapy for patients with elevated plasma cholesterol concentrations [27] . In addition, highcholesterol diet is regarded as an important factor in the development of cardiac diseases, since it leads to development of hyperlipidemia, atherosclerosis, and ischemic heart disease [28] . In our previous study, C-HDL 2 and C-HDL 3 values were increased in the Ajuga iva-HC than the untreated HC group [25] . The increased levels of C-HDL in the HC rats treated with aqueous extract from Ajuga iva may be due to the presence of bioactive molecules like iridoids. Effectively, in this study, iridoids treatments increased C-HDL 2 and C-HDL 3 compared to the untreated group.
In our study, the higher levels of cholesterol associated with HDL and the increase in the activity of serum LCAT in the I 5 -HC and I 10 -HC groups compared to the HC group may result in a higher amount of cholesterol being removed from extra hepatic tissues which may contribute to the hypocholesterolemia observed in these animals. Although the levels of total apo-HDL 3 values, including apoA1, the cofactor-activator of LCAT and PL-HDL 3 (substrate of LCAT) contents, are similar, the EC of HDL 2 , a product of the reaction of LCAT are increased in all iridoids treated groups compared to the untreated group.
In addition, LCAT activity has been traditionally regarded as anti-atherogenic. The increase in LCAT activity observed in this study could, therefore, be a protective mechanism that counteracts iridoidsinduced hyperlipidemia. This study showed that treatment with iridoids (5 and 10 mg/kg b.w) increases the activity of LCAT causing high levels of EC-HDL 2 . By increasing the activity of LCAT with iridoids in these groups, cholesterol previously picked up from peripheral cells by nascent HDL would be esterified at a faster rate. The rate at which newly formed CE contained in HDL could be transferred to apoB-containing lipoproteins for subsequent elimination would also be increased. Taken together, the effects of iridoids on the activity of LCAT would seem to suggest that the iridoids-treated rats were attempting to clear the serum cholesterol burden as rapidly as possible.
To conclude, consuming iridoids from the lyophilized aqueous extract of Ajuga iva reduced triglyceridemia and hypercholesterolemia in hypercholesterolemic rats and specially at doses 5 or 10 mg/kg b.w. Iridoids appeared to ameliorate hypercholesterolemia probably by decreasing the exogenous cholesterol absorption and increasing the endogenous cholesterol conversion to bile acid, though to know the exact mechanism further studies are needed. 
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